Antifibrotic therapy: is an antioxidative regimen the answer?
- PMID: 24179167
- PMCID: PMC3871788
- DOI: 10.1681/ASN.2013101034
Antifibrotic therapy: is an antioxidative regimen the answer?
Comment on
-
Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD.J Am Soc Nephrol. 2014 Jan;25(1):43-54. doi: 10.1681/ASN.2012090962. Epub 2013 Sep 5. J Am Soc Nephrol. 2014. PMID: 24009239 Free PMC article.
References
-
- Boor P, Floege J: The renal (myo-)fibroblast: A heterogeneous group of cells. Nephrol Dial Transplant 27: 3027–3036, 2012 - PubMed
-
- Strutz F: Potential methods to prevent interstitial fibrosis in renal disease. Expert Opin Investig Drugs 10: 1989–2001, 2001 - PubMed
-
- Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC: Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) 17: 311–321, 2012 - PubMed
-
- Kania DS, Smith CT, Nash CL, Gonzalvo JD, Bittner A, Shepler BM: Potential new treatments for diabetic kidney disease. Med Clin North Am 97: 115–134, 2013 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical